SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024. Poster presentations will be available for on-demand viewing beginning on July 28 at 8:00 a.m. ET. AL002 ...

SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5th Annual Neuro Perspectives Conference, being held virtually on Thursday, June 27, 2024. A webcast of the presentation will be available on the "Events & Presentations" page at 7:00 a.m. ET within the Investors section of the Alector website at http: ...

SOUTH SAN FRANSISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host a virtual event to discuss Alector Brain Carrier, a proprietary, versatile blood-brain barrier (BBB) technology platform that is being applied selectively to the Company's next-generation product candidates and research pipeline. The event will include a presentation from Alector's management team as well as a lea ...

SOUTH SAN FRANSISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host a virtual event to discuss Alector Brain Carrier, a proprietary, versatile blood-brain barrier (BBB) technology platform that is being applied selectively to the Company’s next-generation product candidates and research pipeline. The event will include a presentation from Alector’s management team as well as a le ...

Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.83%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.80 per share when it actually produced a loss of $0.49, delivering a surprise of 38.75%.Over the last four quarters, the company has su ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38792 Alector, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-2933343 (State or other jurisdiction of ( ...

Exhibit 99.1 Alector Reports First Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 South S ...

公司背景 - Alector公司是一家临床阶段的生物技术公司，致力于开拓免疫神经学领域[2] - Alector公司的免疫神经学产品候选药物受到生物标志物支持，旨在治疗阿尔茨海默病和遗传定义的额颞叶痴呆患者群体[2] - Alector公司总部位于加利福尼亚州南旧金山[2] 投资者会议 - Alector公司将参加多个投资者会议，包括TD Cowen第44届年度医疗保健大会、Leerink Partners全球生物制药大会、Barclays第26届全球医疗保健大会和Stifel 2024年CNS Days[1]

财务数据和关键指标变化 - 公司2023年第四季度合作收入为1.52亿美元,较2022年同期的1.44亿美元有所增加 [41] - 公司2023年全年合作收入为9.71亿美元,较2022年的13.36亿美元有所下降 [41] - 公司2023年第四季度研发费用为4.77亿美元,较2022年同期的5.45亿美元有所下降 [41] - 公司2023年全年研发费用为19.21亿美元,较2022年的21.04亿美元有所下降 [41] - 公司2023年第四季度管理费用为1.49亿美元,较2022年同期的1.54亿美元有所下降 [41] - 公司2023年全年管理费用为5.67亿美元,较2022年的6.10亿美元有所下降 [41] - 公司预计2024年合作收入将在6-7亿美元之间,研发费用将在21-23亿美元之间,管理费用将在6-7亿美元之间 [42] 各条业务线数据和关键指标变化 - 公司正在开发的主要产品包括TREM2激动剂AL002、前列腺素升高候选药物latozinemab和AL101 [14][24][28] - AL002在2023年第四季度完成了INVOKE-2 II期临床试验的患者入组,正在评估其在早期阿尔茨海默病患者中的疗效和安全性 [15][16][17][18][19][20][21] - latozinemab在2023年10月完成了INFRONT-3 III期临床试验的患者入组,正在评估其在前额叶痴呆伴有progranulin基因突变(FTD-GRN)患者中的疗效 [26][27] - AL101正在与GSK合作开展PROGRESS-AD II期临床试验,评估其在早期阿尔茨海默病患者中的疗效和安全性 [28][29][30] 各个市场数据和关键指标变化 - 未提及具体市场数据和关键指标变化 公司战略和发展方向及行业竞争 - 公司专注于开发针对神经退行性疾病的免疫神经学候选药物,包括针对微小胶质细胞、星形胶质细胞、少突胶质细胞、血脑屏障和血管的治疗手段 [8][9] - 公司认为其免疫神经学候选药物可能会比单纯针对错误折叠蛋白的疗法显示出更强的疗效和更持久的疗效 [9] - 公司正在开发名为Alector Brain Carrier (ABC)的专有血脑屏障技术,以提高药物进入中枢神经系统的效率 [34][35][36][37] - 公司正在加快投资于创新的自有产品管线,包括利用ABC技术的新一代项目 [39][40] 管理层对经营环境和未来前景的评论 - 公司认为2023年取得了成功的临床执行和明确的时间线,并取得了多个重要里程碑 [10][11] - 公司期待在今年和明年看到潜在的重要数据读数 [12] - 公司表示将继续专注于交付并将进展转化为有意义的影响 [12] - 公司认为其先进的管线、强大的现金头寸使其准备好在下一个增长阶段创造重大价值 [12] 问答环节重要的提问和回答 问题1 **Unidentified Analyst 提问** 对于ABC技术,公司是否计划针对不同适应症选择不同的靶点,还是会统一使用某一种靶点? [46] **Sara Kenkare-Mitra 回答** 公司目前正在同时针对转铁蛋白受体(TFR)和CD98重链两个靶点进行研究,并计划根据不同项目的具体需求进行定制。公司的技术具有很强的适应性,可以根据治疗剂量、亲和力、价格等因素进行优化。[47][48] 问题2 **Gary Romano 回答** 对于INVOKE-2试验,公司计划采用一种称为proportional analysis的分析方法,利用所有时间点的数据来评估AL002对阿尔茨海默病进展的影响,而不仅仅是单一时间点的结果。公司认为这种方法可以充分利用所有收集到的数据。[53][54][55] 问题3 **Gary Romano 回答** 公司预计INVOKE-2试验将收集一个非常丰富的生物标志物数据包,包括tau PET成像、血浆磷酸化tau等,这些都将有助于评估AL002是否能够减缓阿尔茨海默病的进展。[57][58][59][60][61]

Exhibit 99.1 Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023 First participant in the global PROGRESS-AD Phase 2 clinical trial of AL101 in early AD dosed in Q1 2024 Latozinemab granted FDA’s Breakthrough Therapy Designation for frontotemporal dementia due to a mutation in the p ...